Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression.

animal model diet fat in vitro in vivo mouse prostate cancer

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
30 Apr 2019
Historique:
received: 22 03 2019
revised: 27 04 2019
accepted: 29 04 2019
entrez: 5 5 2019
pubmed: 6 5 2019
medline: 6 5 2019
Statut: epublish

Résumé

Although recent evidence has suggested that a high-fat diet (HFD) plays an important role in prostate carcinogenesis, the underlying mechanisms have largely remained unknown. This review thus summarizes previous preclinical studies that have used prostate cancer cells and animal models to assess the impact of dietary fat on prostate cancer development and progression. Large variations in the previous studies were found during the selection of preclinical models and types of dietary intervention. Subcutaneous human prostate cancer cell xenografts, such as LNCaP, LAPC-4, and PC-3 and genetic engineered mouse models, such as TRAMP and Pten knockout, were frequently used. The dietary interventions had not been standardized, and distinct variations in the phenotype were observed in different studies using distinct HFD components. The use of different dietary components in the research models is reported to influence the effect of diet-induced metabolic disorders. The proposed underlying mechanisms for HFD-induced prostate cancer were divided into (1) growth factor signaling, (2) lipid metabolism, (3) inflammation, (4) hormonal modulation, and others. A number of preclinical studies proposed that dietary fat and/or obesity enhanced prostate cancer development and progression. However, the relationship still remains controversial, and care should be taken when interpreting the results in a human context. Future studies using more sophisticated preclinical models are imperative in order to explore deeper understanding regarding the impact of dietary fat on the development and progression of prostate cancer.

Identifiants

pubmed: 31052319
pii: jcm8050597
doi: 10.3390/jcm8050597
pmc: PMC6572108
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Urol Oncol. 2000 Nov 1;5(6):274-283
pubmed: 11008096
Cancer Causes Control. 2002 Dec;13(10):929-35
pubmed: 12588089
Prostate. 2003 Aug 1;56(3):201-6
pubmed: 12772189
Clin Cancer Res. 2003 Jul;9(7):2734-43
pubmed: 12855654
Cancer Cell. 2003 Sep;4(3):223-38
pubmed: 14522256
Cancer Res. 2004 Feb 15;64(4):1252-4
pubmed: 14973081
Cancer Res. 2004 Mar 15;64(6):2270-305
pubmed: 15026373
Cell. 2005 Jan 28;120(2):261-73
pubmed: 15680331
J Urol. 2005 Sep;174(3):1065-9; discussion 1069-70
pubmed: 16094059
J Mol Endocrinol. 2006 Jun;36(3):485-501
pubmed: 16720718
Biomed Pharmacother. 2006 Nov;60(9):502-7
pubmed: 17045449
Diabetes. 2007 Jan;56(1):16-23
pubmed: 17192460
Nat Rev Cancer. 2007 Apr;7(4):256-69
pubmed: 17384581
Obesity (Silver Spring). 2007 Apr;15(4):798-808
pubmed: 17426312
J Clin Invest. 2007 Jul;117(7):1866-75
pubmed: 17607361
Prostate. 2008 Jan 1;68(1):11-9
pubmed: 17999389
J Natl Cancer Inst. 2007 Dec 5;99(23):1793-800
pubmed: 18042933
Prostate. 2008 Feb 15;68(3):321-35
pubmed: 18175332
Cancer Res. 2008 Apr 15;68(8):3066-73
pubmed: 18413778
Lancet Oncol. 2008 Nov;9(11):1039-47
pubmed: 18835745
Nutr Res Rev. 2000 Dec;13(2):159-84
pubmed: 19087438
Nature. 2009 Apr 9;458(7239):725-31
pubmed: 19279572
Cancer Prev Res (Phila). 2009 Jun;2(6):557-65
pubmed: 19470786
Eur J Cancer. 2009 Aug;45(12):2077-86
pubmed: 19493674
Annu Rev Med. 2010;61:301-16
pubmed: 19824817
Cancer Res. 2009 Oct 15;69(20):8133-40
pubmed: 19826053
J Urol. 2010 Jan;183(1):345-50
pubmed: 19914662
Int J Cancer. 2010 Oct 1;127(7):1650-9
pubmed: 20073066
Prostate. 2010 Jul 1;70(10):1037-43
pubmed: 20166128
J Urol. 2010 Apr;183(4):1619-24
pubmed: 20172549
Nat Rev Urol. 2010 Aug;7(8):442-53
pubmed: 20647991
Br J Cancer. 1991 Jun;63(6):963-6
pubmed: 2069852
Cancer Prev Res (Phila). 2010 Sep;3(9):1124-31
pubmed: 20716631
Nutr Res Rev. 2010 Dec;23(2):270-99
pubmed: 20977819
Am J Pathol. 2010 Dec;177(6):3180-91
pubmed: 21088217
Cancer Res. 2011 May 1;71(9):3236-45
pubmed: 21415164
Libyan J Med. 2007 Dec 01;2(4):180-4
pubmed: 21503242
Carcinogenesis. 2011 Nov;32(11):1589-96
pubmed: 21828059
Cancer Metastasis Rev. 2011 Dec;30(3-4):295-309
pubmed: 22015690
Carcinogenesis. 2012 Jan;33(1):140-8
pubmed: 22045025
Carcinogenesis. 2012 Feb;33(2):404-12
pubmed: 22159221
Prostate. 2012 Jul 1;72(10):1052-9
pubmed: 22314496
Prostate. 2012 Dec 1;72(16):1779-88
pubmed: 22514016
Mol Cancer Ther. 2012 Jul;11(7):1539-46
pubmed: 22562985
Cancer Metastasis Rev. 2013 Jun;32(1-2):109-22
pubmed: 23114843
Eur Urol. 2013 May;63(5):800-9
pubmed: 23219374
Prostate Cancer. 2012;2012:543970
pubmed: 23304522
Prostate. 2013 Aug;73(11):1223-32
pubmed: 23630020
PLoS Genet. 2013 May;9(5):e1003483
pubmed: 23675307
Endocr Relat Cancer. 2013 Dec 16;21(1):39-50
pubmed: 24344250
Curr Opin Genet Dev. 2014 Feb;24:46-51
pubmed: 24657536
Clin Cancer Res. 2014 Aug 1;20(15):4086-95
pubmed: 24842953
Prostate. 2014 Sep;74(13):1266-77
pubmed: 25053105
Sci Rep. 2014 Aug 05;4:5959
pubmed: 25091112
Actas Urol Esp. 2015 Apr;39(3):161-8
pubmed: 25442907
Nutrients. 2014 Dec 22;6(12):6095-109
pubmed: 25533015
Biomed Res Int. 2015;2015:249741
pubmed: 25722971
Mol Metab. 2015 Jan 02;4(3):186-98
pubmed: 25737954
Nutrients. 2015 Apr 09;7(4):2539-61
pubmed: 25912035
J Biol Methods. 2015;2(1):null
pubmed: 26146646
Cell Death Dis. 2015 Dec 31;6:e2037
pubmed: 26720346
Oncogenesis. 2016 Feb 15;5:e195
pubmed: 26878389
Cancer Res. 2016 Jun 1;76(11):3130-5
pubmed: 27020859
Stem Cell Res. 2016 May;16(3):682-91
pubmed: 27107344
Nat Commun. 2016 May 31;7:11674
pubmed: 27241286
Prostate. 2016 Oct;76(14):1293-302
pubmed: 27338236
Oncotarget. 2016 Jul 26;7(30):47650-47662
pubmed: 27351281
Nutr Metab Insights. 2016 Jul 14;9:43-50
pubmed: 27441003
Carcinogenesis. 2016 Dec;37(12):1129-1137
pubmed: 27915273
Int J Prev Med. 2017 May 25;8:35
pubmed: 28584617
J Biol Chem. 2017 Nov 10;292(45):18422-18433
pubmed: 28939770
Obesity (Silver Spring). 2017 Nov;25(11):1932-1940
pubmed: 28944626
Urol Oncol. 2019 Jun;37(6):387-401
pubmed: 29103966
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nat Genet. 2018 Feb;50(2):206-218
pubmed: 29335545
Oncotarget. 2017 Dec 4;8(67):111780-111794
pubmed: 29340091
Front Oncol. 2018 Jan 18;8:2
pubmed: 29404276
Oncol Lett. 2018 Feb;15(2):1607-1615
pubmed: 29434856
Int J Urol. 2018 Jun;25(6):524-531
pubmed: 29740894
Clin Cancer Res. 2018 Sep 1;24(17):4309-4318
pubmed: 29776955
Prostate Cancer Prostatic Dis. 2018 Jun;21(2):196-203
pubmed: 29795142
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Int J Cancer. 2019 Mar 1;144(5):1115-1127
pubmed: 30152543
Oncol Lett. 2018 Oct;16(4):4945-4952
pubmed: 30250560
Int J Mol Sci. 2019 Feb 15;20(4):null
pubmed: 30781341
J Natl Cancer Inst. 1995 Oct 4;87(19):1456-62
pubmed: 7545759
Cancer Res. 1996 Sep 15;56(18):4096-102
pubmed: 8797572
Int J Cancer. 1977 Nov 15;20(5):680-8
pubmed: 924691
Nutr Cancer. 1997;29(2):114-9
pubmed: 9427973

Auteurs

Shintaro Narita (S)

Department of Urology, Akita University School of Medicine, Akita 010-8543, Japan. naritashintaro@gmail.com.

Taketoshi Nara (T)

Department of Urology, Akita University School of Medicine, Akita 010-8543, Japan. bkspt512@yahoo.co.jp.

Hiromi Sato (H)

Department of Urology, Akita University School of Medicine, Akita 010-8543, Japan. hiromisato2002@yahoo.co.jp.

Atsushi Koizumi (A)

Department of Urology, Akita University School of Medicine, Akita 010-8543, Japan. koizu3atsu4@yahoo.co.jp.

Mingguo Huang (M)

Department of Urology, Akita University School of Medicine, Akita 010-8543, Japan. huangmg0319@yahoo.co.jp.

Takamitsu Inoue (T)

Department of Urology, Akita University School of Medicine, Akita 010-8543, Japan. takmitz@gmail.com.

Tomonori Habuchi (T)

Department of Urology, Akita University School of Medicine, Akita 010-8543, Japan. thabuchi@gmail.com.

Classifications MeSH